Evidence map›Paper›PMID 42775256›Full record

ArticleMedicine international

Effectiveness of Tamaru method plasma therapy: Overview and the original method.

Hiroyuki Ono, Takuji Yamaguchi, Ailing Hu, Naoto Hayashida, Hisashi Takeuchi

Abstract read
In one paragraph

Article in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hiroyuki OnoATP Salus Laboratory Inc., Tokyo 107-0052, Japan.
Takuji YamaguchiDepartment of Personalized Kampo Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.
Ailing HuDepartment of Personalized Kampo Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.
Naoto HayashidaDepartment of Preventive and Community Dentistry, Nippon Dental University, Tokyo 102-8159, Japan.
Hisashi TakeuchiJapan Society of Advanced Medical Sciences, Tokyo 151-0063, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid aging of the population in Japan has led to an increased incidence of cancer, creating a demand for effective therapeutic options with minimal physical and financial burden. Non-equilibrium atmospheric pressure plasma (NEAPP), or low-temperature plasma, has emerged as a promising modality in oncology. The present study summarizes the fundamental principles of NEAPP and its therapeutic applications in cancer treatment. The authors first provide an overview of established approaches, such as the direct irradiation of cancer cells and the indirect use of plasma-activated medium, which have been shown to induce apoptosis in malignant cells. Subsequently, the authors introduce a novel therapeutic system, the Tamaru Method Plasma Therapy, developed by the authors' research group. This system combines a unique plasma-generating device, termed Plasma AIAS, with the oral intake of plasma-activated water. The proposed mechanism of this non-invasive method is the systemic enhancement of intracellular adenosine triphosphate production and the generation of nitric oxide. This dual action is expected to improve microcirculation and exert anti-tumor effects, while maintaining a high safety profile. The present study highlights the potential of this original method as a next-generation therapy for cancer, addressing the needs of modern medical care.

Indexed as

adenosine triphosphateelderly cancer carenitric oxidenon-equilibrium atmospheric pressure plasmanon-invasive therapyplasma oncologyreactive oxygen species

Identifiers

PMID42775256
PMCPMC13596025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.